In-vitro CEST MRI reveals NAD+ contrasts and sensitivity for biomarkers in neurodegenerative diseases, suggesting improved diagnostics.
Motivation: Neurodegenerative diseases, particularly Alzheimer's, involve disrupted NAD+ and purine metabolic pathways. Understanding these disruptions can improve diagnostic sensitivity for clinical applications, especially using CEST MRI. Goal(s): To characterise in-vitro CEST MRI properties of NAD+ and its biosynthesis precursors, focusing on sensitivity for neurodegenerative disease biomarkers linked to NAD+/purine metabolism. Approach: In-vitro CEST MRI was used to analyse NAD+ and biosynthesis precursors, quantifying, characterising, and assigning distinct proton peaks to assess sensitivity as neurodegenerative disease biomarkers. Results: High CEST contrast was achieved for NMN and NAD+, with NAD+ showing pH-dependent effects and up to 15% CEST contrast for its amine moiety (2.03ppm). Impact: This study may impact neurodegenerative disease research by enabling precise CEST MRI-based tracking of NAD+ metabolism, specifically adenosine-linked pathways as elucidated (2.03ppm). This could deepen understanding of metabolic disruptions, opening new avenues for early diagnosis and targeted therapeutic monitoring.
No takes yet. Share an insight, caveat, or question.
Slade et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: